Now Available…

Test 182: Aerobic Vaginitis (AV) Panel by Real-Time PCR

Includes:
- Group B Streptococcus (GBS)
- Enterococcus faecalis
- Escherichia coli
- Staphylococcus aureus

- Up to 20% of patients with Bacterial Vaginosis (BV) will fail to respond to metronidazole treatment.
- Aerobic Vaginitis (AV) has overlapping symptoms with BV and may account for a subset of such patients.
- The utilization of the AV panel for a differential diagnosis can be used to prescribe an effective treatment regimen.
- Published reports indicate an association of AV with PROM and Preterm delivery.
- Highly sensitive and specific real-time PCR technology.
- 24 – 48 hour turnaround time.
FOR IMMEDIATE RELEASE


Hamilton, NJ., April 10, 2012—Medical Diagnostic Laboratories, L.L.C., (MDL), is a CLIA certified infectious disease laboratory specializing in high complexity, state-of-the-art, automated, DNA-based molecular analyses. By using molecular techniques, MDL is able to provide clinicians from many different specialties with valuable information to assist them in the diagnosis, evaluation, and treatment of viral, fungal, and bacterial infections.

MDL, a member of the Genesis Biotechnology Group (GBG), is located in “Einstein’s Alley,” the research and technology corridor that runs from Princeton to Hamilton, New Jersey. GBG’s headquarters is easily accessible from the tri-state area that includes New York, New Jersey, and Pennsylvania.

Femeris Women’s Health Research Center™, an MDL institute, was established to translate women’s health research into diagnostic tests. This new Aerobic Vaginitis (AV) Panel by PCR, available through MDL, will provide another tool for clinicians to accurately diagnosis diseases associated with abnormal levels of vaginal flora, thereby facilitating proper treatment regimens to achieve an effective cure.

AV is caused by the overgrowth of aerobic pathogens such as Escherichia coli, Group B Streptococcus, Staphylococcus aureus, and Enterococcus faecalis that trigger a localized vaginal inflammatory immune response as evidenced by clinical signs and symptoms, including the presence of vaginal discharge, an elevation of the vaginal pH, inflammation with leukocyte infiltration and a marked depletion of healthy Lactobacillus species. There are important distinctions between AV and Bacterial Vaginosis (BV). Unlike AV, BV is a common vaginal disorder associated with the overgrowth of anaerobic bacteria and a distinct vaginal, malodorous discharge, but is not usually associated with a strong vaginal inflammatory immune response. BV is traditionally treated with metronidazole therapy that targets anaerobic bacteria. However, approximately 20% of women diagnosed with BV and treated with metronidazole will fail to respond to therapy and will experience a recurrence of symptoms. Often these patients are misdiagnosed and actually suffer from AV, which requires an antibiotic therapy against the aerobic bacteria. AV has been implicated in complications of pregnancy such as ascending chorioamnionitis, premature rupture of the membranes and preterm delivery.

According to Dr. Eli Mordechai, Chief Executive Officer (CEO), “This test offering is another example of MDL’s efforts to provide tailored, molecular diagnostic approaches to address polymicrobial-based, chronic, persistent, and complex diseases. Recently, we introduced another ground-breaking test for Bacterial Vaginosis which offers Lactobacillus profiling analysis, at no additional charge. This new Aerobic Vaginitis test provides the physician with valuable data that is essential for a patient's stratification, therapy and prognosis. MDL’s selective molecular testing platforms are specifically designed to address chronic diseases well beyond the identification of a specific pathogen. Such advances as demonstrated by many other tests currently offered by MDL are possible by extending traditional detection assays to include molecular antimicrobial resistance profiles and genetic surrogate markers.”

For more information, please visit www.mdlab.com.

Contact:
Scott Gygax, Ph.D.
sygax@mdlab.com
609.570.1015
www.mdlab.com